Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 494

1.

Evaluation of ERK as a therapeutic target in acute myelogenous leukemia.

Weisberg E, Meng C, Case A, Sattler M, Tiv HL, Gokhale PC, Buhrlage S, Wang J, Gray N, Stone R, Liu S, Bhagwat SV, Tiu RV, Adamia S, Griffin JD.

Leukemia. 2019 Aug 27. doi: 10.1038/s41375-019-0552-3. [Epub ahead of print] No abstract available.

PMID:
31455850
2.

Antigen-specific immune decoys intercept and exhaust autoimmunity to prevent disease.

Griffin JD, Song JY, Huang A, Sedlacek AR, Flannagan KL, Berkland CJ.

Biomaterials. 2019 Nov;222:119440. doi: 10.1016/j.biomaterials.2019.119440. Epub 2019 Aug 19.

PMID:
31450159
3.

Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies.

Weisberg E, Meng C, Case AE, Sattler M, Tiv HL, Gokhale PC, Buhrlage SJ, Liu X, Yang J, Wang J, Gray N, Stone RM, Adamia S, Dubreuil P, Letard S, Griffin JD.

Br J Haematol. 2019 Jul 15. doi: 10.1111/bjh.16092. [Epub ahead of print]

PMID:
31309543
4.

Correction: AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL.

Weisberg E, Manley P, Mestan J, Cowan-Jacob S, Ray A, Griffin JD.

Br J Cancer. 2019 Jul;121(3):282. doi: 10.1038/s41416-019-0505-7.

5.

Acute B-Cell Inhibition by Soluble Antigen Arrays Is Valency-Dependent and Predicts Immunomodulation in Splenocytes.

Griffin JD, Leon MA, Salash JR, Shao M, Hartwell BL, Pickens CJ, Sestak JO, Berkland C.

Biomacromolecules. 2019 May 13;20(5):2115-2122. doi: 10.1021/acs.biomac.9b00328. Epub 2019 May 2.

PMID:
30995843
6.

Tocopherol Emulsions as Functional Autoantigen Delivery Vehicles Evoke Therapeutic Efficacy in Experimental Autoimmune Encephalomyelitis.

Griffin JD, Christopher MA, Thati S, Salash JR, Pressnall MM, Weerasekara DB, Lunte SM, Berkland CJ.

Mol Pharm. 2019 Feb 4;16(2):607-617. doi: 10.1021/acs.molpharmaceut.8b00887. Epub 2019 Jan 17.

7.

Treatment patterns and healthcare resource utilization in patients with FLT3-mutated and wild-type acute myeloid leukemia: A medical chart study.

Griffin JD, Yang H, Song Y, Kinrich D, Shah MV, Bui CN.

Eur J Haematol. 2019 Apr;102(4):341-350. doi: 10.1111/ejh.13205. Epub 2019 Feb 5.

PMID:
30578743
8.

Distribution, Prevalence, and Maximum Intensity of the Ectoparasitic Copepod Salmincola cf. Edwardsii in Brook Trout in Wisconsin Streams.

Mitro MG, Griffin JD.

J Parasitol. 2018 Dec;104(6):628-638. doi: 10.1645/17-146. Epub 2018 Aug 29.

PMID:
30138083
9.

Notch1 activation enhances proliferation via activation of cdc2 and delays differentiation of myeloid progenitors.

Nakamura M, Wu L, Griffin JD, Kojika S, Goi K, Inukai T, Sugita K.

Leuk Res. 2018 Sep;72:34-44. doi: 10.1016/j.leukres.2018.07.022. Epub 2018 Jul 30.

10.

Soluble antigen arrays disarm antigen-specific B cells to promote lasting immune tolerance in experimental autoimmune encephalomyelitis.

Hartwell BL, Pickens CJ, Leon M, Northrup L, Christopher MA, Griffin JD, Martinez-Becerra F, Berkland C.

J Autoimmun. 2018 Sep;93:76-88. doi: 10.1016/j.jaut.2018.06.006. Epub 2018 Jul 13.

11.

A role for long-chain acyl-CoA synthetase-4 (ACSL4) in diet-induced phospholipid remodeling and obesity-associated adipocyte dysfunction.

Killion EA, Reeves AR, El Azzouny MA, Yan QW, Surujon D, Griffin JD, Bowman TA, Wang C, Matthan NR, Klett EL, Kong D, Newman JW, Han X, Lee MJ, Coleman RA, Greenberg AS.

Mol Metab. 2018 Mar;9:43-56. doi: 10.1016/j.molmet.2018.01.012. Epub 2018 Jan 31.

12.

Spotlight on midostaurin in the treatment of FLT3-mutated acute myeloid leukemia and systemic mastocytosis: design, development, and potential place in therapy.

Weisberg E, Sattler M, Manley PW, Griffin JD.

Onco Targets Ther. 2017 Dec 29;11:175-182. doi: 10.2147/OTT.S127679. eCollection 2018. Review.

13.

Inhibition of SDF-1-induced migration of oncogene-driven myeloid leukemia by the L-RNA aptamer (Spiegelmer), NOX-A12, and potentiation of tyrosine kinase inhibition.

Weisberg EL, Sattler M, Azab AK, Eulberg D, Kruschinski A, Manley PW, Stone R, Griffin JD.

Oncotarget. 2017 Nov 6;8(66):109973-109984. doi: 10.18632/oncotarget.22409. eCollection 2017 Dec 15.

14.

A Shared Understanding: Managing Aesthetic Treatment Imperfection.

Griffin JD Jr.

Dent Today. 2017 Mar;36(3):90, 92, 94-5. No abstract available.

PMID:
29235572
15.

Midostaurin, a Natural Product-Derived Kinase Inhibitor Recently Approved for the Treatment of Hematological MalignanciesPublished as part of the Biochemistry series "Biochemistry to Bedside".

Manley PW, Weisberg E, Sattler M, Griffin JD.

Biochemistry. 2018 Feb 6;57(5):477-478. doi: 10.1021/acs.biochem.7b01126. Epub 2017 Nov 30. No abstract available.

16.

CAD/CAM Restorations: Achieving Excellence and Simplicity.

Griffin JD Jr.

Dent Today. 2016 Nov;35(11):96,98, 100. No abstract available.

PMID:
29185607
17.

A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader.

Huang HT, Dobrovolsky D, Paulk J, Yang G, Weisberg EL, Doctor ZM, Buckley DL, Cho JH, Ko E, Jang J, Shi K, Choi HG, Griffin JD, Li Y, Treon SP, Fischer ES, Bradner JE, Tan L, Gray NS.

Cell Chem Biol. 2018 Jan 18;25(1):88-99.e6. doi: 10.1016/j.chembiol.2017.10.005. Epub 2017 Nov 9.

18.

Acute myeloid leukemia cells require 6-phosphogluconate dehydrogenase for cell growth and NADPH-dependent metabolic reprogramming.

Bhanot H, Weisberg EL, Reddy MM, Nonami A, Neuberg D, Stone RM, Podar K, Salgia R, Griffin JD, Sattler M.

Oncotarget. 2017 Jun 28;8(40):67639-67650. doi: 10.18632/oncotarget.18797. eCollection 2017 Sep 15.

19.

Inhibition of USP10 induces degradation of oncogenic FLT3.

Weisberg EL, Schauer NJ, Yang J, Lamberto I, Doherty L, Bhatt S, Nonami A, Meng C, Letai A, Wright R, Tiv H, Gokhale PC, Ritorto MS, De Cesare V, Trost M, Christodoulou A, Christie A, Weinstock DM, Adamia S, Stone R, Chauhan D, Anderson KC, Seo HS, Dhe-Paganon S, Sattler M, Gray NS, Griffin JD, Buhrlage SJ.

Nat Chem Biol. 2017 Dec;13(12):1207-1215. doi: 10.1038/nchembio.2486. Epub 2017 Oct 2.

20.

Co-delivery of autoantigen and dexamethasone in incomplete Freund's adjuvant ameliorates experimental autoimmune encephalomyelitis.

Northrup L, Griffin JD, Christopher MA, Antunez LR, Hartwell BL, Pickens CJ, Berkland C.

J Control Release. 2017 Nov 28;266:156-165. doi: 10.1016/j.jconrel.2017.09.034. Epub 2017 Sep 28.

21.

Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase.

Weisberg EL, Puissant A, Stone R, Sattler M, Buhrlage SJ, Yang J, Manley PW, Meng C, Buonopane M, Daley JF, Lazo S, Wright R, Weinstock DM, Christie AL, Stegmaier K, Griffin JD.

Oncotarget. 2017 Jul 6;8(32):52026-52044. doi: 10.18632/oncotarget.19036. eCollection 2017 Aug 8.

22.

Genetic architecture of wild soybean (Glycine soja) response to soybean cyst nematode (Heterodera glycines).

Zhang H, Song Q, Griffin JD, Song BH.

Mol Genet Genomics. 2017 Dec;292(6):1257-1265. doi: 10.1007/s00438-017-1345-x. Epub 2017 Jul 14.

23.

Predictive Processing, Source Monitoring, and Psychosis.

Griffin JD, Fletcher PC.

Annu Rev Clin Psychol. 2017 May 8;13:265-289. doi: 10.1146/annurev-clinpsy-032816-045145. Epub 2017 Mar 30. Review.

24.

Reversing the Regioselectivity of Halofunctionalization Reactions through Cooperative Photoredox and Copper Catalysis.

Griffin JD, Cavanaugh CL, Nicewicz DA.

Angew Chem Int Ed Engl. 2017 Feb 13;56(8):2097-2100. doi: 10.1002/anie.201610722. Epub 2017 Jan 20.

25.

Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors.

Tan L, Gurbani D, Weisberg EL, Jones DS, Rao S, Singer WD, Bernard FM, Mowafy S, Jenney A, Du G, Nonami A, Griffin JD, Lauffenburger DA, Westover KD, Sorger PK, Gray NS.

Bioorg Med Chem. 2017 Feb 15;25(4):1320-1328. doi: 10.1016/j.bmc.2016.11.034. Epub 2016 Dec 7.

26.

Structure-guided development of covalent TAK1 inhibitors.

Tan L, Gurbani D, Weisberg EL, Hunter JC, Li L, Jones DS, Ficarro SB, Mowafy S, Tam CP, Rao S, Du G, Griffin JD, Sorger PK, Marto JA, Westover KD, Gray NS.

Bioorg Med Chem. 2017 Feb 1;25(3):838-846. doi: 10.1016/j.bmc.2016.11.035. Epub 2016 Dec 9.

27.

Genome-Wide Association Study of Resistance to Soybean Cyst Nematode (Heterodera glycines) HG Type 2.5.7 in Wild Soybean (Glycine soja).

Zhang H, Li C, Davis EL, Wang J, Griffin JD, Kofsky J, Song BH.

Front Plant Sci. 2016 Aug 17;7:1214. doi: 10.3389/fpls.2016.01214. eCollection 2016.

28.

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

Townsend EC, Murakami MA, Christodoulou A, Christie AL, Köster J, DeSouza TA, Morgan EA, Kallgren SP, Liu H, Wu SC, Plana O, Montero J, Stevenson KE, Rao P, Vadhi R, Andreeff M, Armand P, Ballen KK, Barzaghi-Rinaudo P, Cahill S, Clark RA, Cooke VG, Davids MS, DeAngelo DJ, Dorfman DM, Eaton H, Ebert BL, Etchin J, Firestone B, Fisher DC, Freedman AS, Galinsky IA, Gao H, Garcia JS, Garnache-Ottou F, Graubert TA, Gutierrez A, Halilovic E, Harris MH, Herbert ZT, Horwitz SM, Inghirami G, Intlekofer AM, Ito M, Izraeli S, Jacobsen ED, Jacobson CA, Jeay S, Jeremias I, Kelliher MA, Koch R, Konopleva M, Kopp N, Kornblau SM, Kung AL, Kupper TS, LeBoeuf NR, LaCasce AS, Lees E, Li LS, Look AT, Murakami M, Muschen M, Neuberg D, Ng SY, Odejide OO, Orkin SH, Paquette RR, Place AE, Roderick JE, Ryan JA, Sallan SE, Shoji B, Silverman LB, Soiffer RJ, Steensma DP, Stegmaier K, Stone RM, Tamburini J, Thorner AR, van Hummelen P, Wadleigh M, Wiesmann M, Weng AP, Wuerthner JU, Williams DA, Wollison BM, Lane AA, Letai A, Bertagnolli MM, Ritz J, Brown M, Long H, Aster JC, Shipp MA, Griffin JD, Weinstock DM.

Cancer Cell. 2016 Jul 11;30(1):183. doi: 10.1016/j.ccell.2016.06.008. Epub 2016 Jul 11. No abstract available.

29.

Simultaneous inhibition of Vps34 kinase would enhance PI3Kδ inhibitor cytotoxicity in the B-cell malignancies.

Liu X, Wang A, Liang X, Liu J, Zou F, Chen C, Zhao Z, Deng Y, Wu H, Qi Z, Wang B, Wang L, Liu F, Xu Y, Wang W, Fernandes SM, Stone RM, Galinsky IA, Brown JR, Loh T, Griffin JD, Zhang S, Weisberg EL, Zhang X, Liu J, Liu Q.

Oncotarget. 2016 Aug 16;7(33):53515-53525. doi: 10.18632/oncotarget.10650.

30.

Discovery of a highly potent FLT3 kinase inhibitor for FLT3-ITD-positive AML.

Wu H, Wang A, Qi Z, Li X, Chen C, Yu K, Zou F, Hu C, Wang W, Zhao Z, Wu J, Liu J, Liu X, Wang L, Wang W, Zhang S, Stone RM, Galinsky IA, Griffin JD, Weinstock D, Christodoulou A, Wang H, Shen Y, Zhai Z, Weisberg EL, Liu J, Liu Q.

Leukemia. 2016 Oct;30(10):2112-2116. doi: 10.1038/leu.2016.151. Epub 2016 May 25. No abstract available.

31.

Discovery of a Highly Potent and Selective Indenoindolone Type 1 Pan-FLT3 Inhibitor.

Hatcher JM, Weisberg E, Sim T, Stone RM, Liu S, Griffin JD, Gray NS.

ACS Med Chem Lett. 2016 Mar 8;7(5):476-81. doi: 10.1021/acsmedchemlett.5b00498. eCollection 2016 May 12.

32.

Characterization of selective and potent PI3Kδ inhibitor (PI3KDIN- 015) for B-Cell malignances.

Liu X, Wang A, Liang X, Chen C, Liu J, Zhao Z, Wu H, Deng Y, Wang L, Wang B, Wu J, Liu F, Fernandes SM, Adamia S, Stone RM, Galinsky IA, Brown JR, Griffin JD, Zhang S, Loh T, Zhang X, Wang W, Weisberg EL, Liu J, Liu Q.

Oncotarget. 2016 May 31;7(22):32641-51. doi: 10.18632/oncotarget.8702.

33.

Dual inhibition of AKT/FLT3-ITD by A674563 overcomes FLT3 ligand-induced drug resistance in FLT3-ITD positive AML.

Wang A, Wu H, Chen C, Hu C, Qi Z, Wang W, Yu K, Liu X, Zou F, Zhao Z, Wu J, Liu J, Liu F, Wang L, Stone RM, Galinksy IA, Griffin JD, Zhang S, Weisberg EL, Liu J, Liu Q.

Oncotarget. 2016 May 17;7(20):29131-42. doi: 10.18632/oncotarget.8675.

34.

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

Townsend EC, Murakami MA, Christodoulou A, Christie AL, Köster J, DeSouza TA, Morgan EA, Kallgren SP, Liu H, Wu SC, Plana O, Montero J, Stevenson KE, Rao P, Vadhi R, Andreeff M, Armand P, Ballen KK, Barzaghi-Rinaudo P, Cahill S, Clark RA, Cooke VG, Davids MS, DeAngelo DJ, Dorfman DM, Eaton H, Ebert BL, Etchin J, Firestone B, Fisher DC, Freedman AS, Galinsky IA, Gao H, Garcia JS, Garnache-Ottou F, Graubert TA, Gutierrez A, Halilovic E, Harris MH, Herbert ZT, Horwitz SM, Inghirami G, Intlekofer AM, Ito M, Izraeli S, Jacobsen ED, Jacobson CA, Jeay S, Jeremias I, Kelliher MA, Koch R, Konopleva M, Kopp N, Kornblau SM, Kung AL, Kupper TS, LeBoeuf NR, LaCasce AS, Lees E, Li LS, Look AT, Murakami M, Muschen M, Neuberg D, Ng SY, Odejide OO, Orkin SH, Paquette RR, Place AE, Roderick JE, Ryan JA, Sallan SE, Shoji B, Silverman LB, Soiffer RJ, Steensma DP, Stegmaier K, Stone RM, Tamburini J, Thorner AR, van Hummelen P, Wadleigh M, Wiesmann M, Weng AP, Wuerthner JU, Williams DA, Wollison BM, Lane AA, Letai A, Bertagnolli MM, Ritz J, Brown M, Long H, Aster JC, Shipp MA, Griffin JD, Weinstock DM.

Cancer Cell. 2016 Apr 11;29(4):574-586. doi: 10.1016/j.ccell.2016.03.008. Erratum in: Cancer Cell. 2016 Jul 11;30(1):183.

35.

Blood's 70th anniversary: arsenic--from poison pill to magic bullet.

Griffin JD.

Blood. 2016 Apr 7;127(14):1729-30. doi: 10.1182/blood-2015-10-638650. No abstract available.

36.

FOCUS ON: Regenerative Dentistry.

Griffin JD Jr.

Dent Today. 2016 Feb;35(2):14. No abstract available.

PMID:
26995828
37.

Acyl CoA synthetase 5 (ACSL5) ablation in mice increases energy expenditure and insulin sensitivity and delays fat absorption.

Bowman TA, O'Keeffe KR, D'Aquila T, Yan QW, Griffin JD, Killion EA, Salter DM, Mashek DG, Buhman KK, Greenberg AS.

Mol Metab. 2016 Jan 11;5(3):210-220. doi: 10.1016/j.molmet.2016.01.001. eCollection 2016 Mar.

38.

Gene expression profiling analysis of CRTC1-MAML2 fusion oncogene-induced transcriptional program in human mucoepidermoid carcinoma cells.

Chen J, Li JL, Chen Z, Griffin JD, Wu L.

BMC Cancer. 2015 Oct 26;15:803. doi: 10.1186/s12885-015-1827-3.

39.

Regenerative Materials Where They Matter Most.

Griffin JD Jr.

Dent Today. 2015 Apr;34(4):124, 126-7. No abstract available.

PMID:
26470568
40.

Xenopus borealis as an alternative source of oocytes for biophysical and pharmacological studies of neuronal ion channels.

Cristofori-Armstrong B, Soh MS, Talwar S, Brown DL, Griffin JD, Dekan Z, Stow JL, King GF, Lynch JW, Rash LD.

Sci Rep. 2015 Oct 6;5:14763. doi: 10.1038/srep14763.

41.

Identification of ILK as a novel therapeutic target for acute and chronic myeloid leukemia.

de la Puente P, Weisberg E, Muz B, Nonami A, Luderer M, Stone RM, Melo JV, Griffin JD, Azab AK.

Leuk Res. 2015 Sep 9. pii: S0145-2126(15)30377-5. doi: 10.1016/j.leukres.2015.09.005. [Epub ahead of print]

42.

Hydrodecarboxylation of Carboxylic and Malonic Acid Derivatives via Organic Photoredox Catalysis: Substrate Scope and Mechanistic Insight.

Griffin JD, Zeller MA, Nicewicz DA.

J Am Chem Soc. 2015 Sep 9;137(35):11340-8. doi: 10.1021/jacs.5b07770. Epub 2015 Aug 28.

43.

Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097.

Weisberg E, Halilovic E, Cooke VG, Nonami A, Ren T, Sanda T, Simkin I, Yuan J, Antonakos B, Barys L, Ito M, Stone R, Galinsky I, Cowens K, Nelson E, Sattler M, Jeay S, Wuerthner JU, McDonough SM, Wiesmann M, Griffin JD.

Mol Cancer Ther. 2015 Oct;14(10):2249-59. doi: 10.1158/1535-7163.MCT-15-0429. Epub 2015 Jul 23.

44.

Discovery of a BTK/MNK dual inhibitor for lymphoma and leukemia.

Wu H, Hu C, Wang A, Weisberg EL, Chen Y, Yun CH, Wang W, Liu Y, Liu X, Tian B, Wang J, Zhao Z, Liang Y, Li B, Wang L, Wang B, Chen C, Buhrlage SJ, Qi Z, Zou F, Nonami A, Li Y, Fernandes SM, Adamia S, Stone RM, Galinsky IA, Wang X, Yang G, Griffin JD, Brown JR, Eck MJ, Liu J, Gray NS, Liu Q.

Leukemia. 2016 Jan;30(1):173-81. doi: 10.1038/leu.2015.180. Epub 2015 Jul 13.

45.

Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML.

Wu H, Hu C, Wang A, Weisberg EL, Wang W, Chen C, Zhao Z, Yu K, Liu J, Wu J, Nonami A, Wang L, Wang B, Stone RM, Liu S, Griffin JD, Liu J, Liu Q.

Leukemia. 2016 Mar;30(3):754-7. doi: 10.1038/leu.2015.175. Epub 2015 Jul 3. No abstract available.

46.

Subcutaneous and segmental fat loss with and without supportive supplements in conjunction with a low-calorie high protein diet in healthy women.

Falcone PH, Tai CY, Carson LR, Joy JM, Mosman MM, Vogel RM, McCann TR, Crona KP, Griffin JD, Kim MP, Moon JR.

PLoS One. 2015 Apr 15;10(4):e0123854. doi: 10.1371/journal.pone.0123854. eCollection 2015.

47.

Identification of novel therapeutic targets in acute leukemias with NRAS mutations using a pharmacologic approach.

Nonami A, Sattler M, Weisberg E, Liu Q, Zhang J, Patricelli MP, Christie AL, Saur AM, Kohl NE, Kung AL, Yoon H, Sim T, Gray NS, Griffin JD.

Blood. 2015 May 14;125(20):3133-43. doi: 10.1182/blood-2014-12-615906. Epub 2015 Apr 1.

48.

Pathological glycogenesis through glycogen synthase 1 and suppression of excessive AMP kinase activity in myeloid leukemia cells.

Bhanot H, Reddy MM, Nonami A, Weisberg EL, Bonal D, Kirschmeier PT, Salgia S, Podar K, Galinsky I, Chowdary TK, Neuberg D, Tonon G, Stone RM, Asara J, Griffin JD, Sattler M.

Leukemia. 2015 Jul;29(7):1555-1563. doi: 10.1038/leu.2015.46. Epub 2015 Feb 23.

49.

Identification of antipsychotic drug fluspirilene as a potential p53-MDM2 inhibitor: a combined computational and experimental study.

Patil SP, Pacitti MF, Gilroy KS, Ruggiero JC, Griffin JD, Butera JJ, Notarfrancesco JM, Tran S, Stoddart JW.

J Comput Aided Mol Des. 2015 Feb;29(2):155-63. doi: 10.1007/s10822-014-9811-6. Epub 2014 Nov 7.

PMID:
25377899
50.

Combination therapy with nilotinib for drug-sensitive and drug-resistant BCR-ABL-positive leukemia and other malignancies.

Weisberg E, Nonami A, Griffin JD.

Arch Toxicol. 2014 Dec;88(12):2233-42. doi: 10.1007/s00204-014-1385-5. Epub 2014 Oct 21. Review.

PMID:
25331939

Supplemental Content

Loading ...
Support Center